Skip to content
Color bar
EAHP

Search

Language

Congress

Forum

EJHP

Members

Home
CARDIOVASCULAR RISK AND ALTERED LIPID PROFILE ASSOCIATED WITH TREATMENT WITH THE KINASE-JAK INHIBITORS, TOFACITINIB AND BARICITINIB
  • Who we are
  • Board
  • Staff
  • Members
  • EAHP Standing Committees
  • Congress
  • BOOST
  • Synergy Masterclasses
  • Synergy Certification Courses
  • GPIs
  • Calendar
  • Members' Event
  • Academy Seminar
  • What hospital pharmacists do
  • European Statement of Hospital Pharmacy
  • SIGs
  • Environmental Sustainability
  • Common training framework
  • Oath to Society
  • Hospital Pharmacy Day
  • Policy
  • Press releases
  • EAHP Publications
  • EJHP
  • EAHP in the news
  • EU Monitors
Facebook Linkedin Instagram X-twitter Youtube
Contact us
Disclaimer
Privacy Policy
Cookie Policy
About this website and online policy
Copyright

© 2024 European Association of Hospital Pharmacists • All Rights Reserved

Boulevard Brand Whitlock 87Box 11 (4th floor) 1200 Brussels​

+32 (0) 2/669.25.15

+32 (0) 2/669.25.29

DIGI-WORK-logo-red

Developed by digi-work.com

×

DISCOUNTED FEE ENDS
JANUARY 31st - REGISTER NOW!

JOIN US!

 

REGISTER HERE!